Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9978416 | Journal of the Saudi Heart Association | 2018 | 7 Pages |
Abstract
The eligibility for statin therapy was much higher when applying the ACC/AHA guideline as compared to ATP-III guideline. Applying the recent ACC/AHA dyslipidemia guideline increased the number of patients eligible for statin therapy to approximately two folds. This would be associated with a substantial increase in cost and possibly side effects. The concerns surrounding the ACC/AHA guideline should be addressed at the national level.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Salahdein Aburuz, Abdulkareem Al-Bekairy, Abdul-Aziz Alqahtani, Khalid Harbi, Mohammed Al Nuhait, Abdullah Khoja, Adel Sadeq, Mohammed Al Rashed,